Connect with us

Lifestyle

2 Men Hacked themselves to Death over Woman

Published

on

2 Men Hacked themselves to Death over Woman

Two men have died while fighting over a woman at Kiyunga, Kyampisi sub county in Mukono district, Uganda.

Men die over woman

The deceased, Hassan Kiwango, 45, and 48-year-old Hakim Katende, reportedly hacked themselves to death on Saturday, September 26, 2020.

GISTFLASH learnt that Katende has been accusing Kiwango of having an affair with his wife ‘Dorothy Birungi.’ (the mother of his 2 kids) for over a year.

I want to be a police officer to fight corruption’- boy in ‘mummy calm down’ video

According to the Observer, the dispute between the two men had attracted the attention of the local council committee, who summoned them to a meeting on Saturday morning.

However, things took a sad turn, when during the meeting, Katende allegedly attacked Kiwango and repeated him cut him on his neck, hands and back. Kiwango also retaliated, leaving both men with grave injuries.

Kampala Metropolitan Police spokesperson, Patrick Onyango, who confirmed the incident, said the two bodies have been taken to Kayunga hospital for postmortem as children and the wife to Katende are held at police for their safety.

Comments
Please follow and like us:

Politics

Traditional ruler of Ewu, Ekiti state escapes death

Published

on

Traditional ruler of Ewu, Ekiti state escapes death
Adetutu Ajayi, the traditional ruler of Ewu Ekiti in Ilejemeje local government (LGA) of Ekiti state, have been shot by hoodlums.

According to NAN, he was shot on Friday night on his way to Ayetoro Ekiti, a neighboring community in Ido/Osi LGA.

The traditional ruler, however, escaped with injuries on his legs, arms and stomach, and he is currently receiving treatment in an undisclosed tertiary medical facility.

Sunday Abutu, the state police spokesman, confirmed the incident.

Abutu said the command is worried that such an attack could be launched in spite of unrelenting joint security patrol and raiding of black-spots to dislodge criminals.

He, however, said the police command in the state is committed to ridding the state of criminals and assured the residents that the perpetrators will be brought to justice.

ALSO READ;

The spokesman said the command will continue to work with other security agencies to ensure that criminality is wiped out in Ekiti.

Reacting to the incident, Ekiti state council of Obas called on security agencies to apprehend the hoodlums and bring them to justice.

Adebanji Alabi, chairman of the council, expressed concern over the rise in banditry and other criminal activities in the country.

He asked the government and security agencies to raise their level of surveillance in the state with a view to reducing crime.

Comments

Please follow and like us:

Continue Reading

Economy

CBN gets order to freeze 194 accounts in 17 banks

Published

on

CBN gets order to freeze 194 accounts in 17 banks

The Central Bank of Nigeria, CBN has secured three separate interim orders from a Federal High Court in Abuja to freeze bank accounts linked to 194 business entities and individuals in 17 banks.

This was contained in a post by the apex bank on its website yesterday pursuant to the court order. The freeze orders were sequel to three exparte applications filed by the apex bank seeking a mandatory order of the court to ask the 17 banks to freeze the account of the business organizations and individual pending the outcome of an ongoing investigation the apex bank had initiated.

In one of the suits against Nuru Abubakar and 24 others, the court granted the request by CBN to freeze the account of the defendants in the banks for 45 days. Justice A.R Muhammed who made the order in his ruling on March 30, 2021, said: “An interim order is hereby made empowering the applicant to direct the head office of the listed banks to freeze forthwith all transactions on the bank account of the defendants for a period of 45 days pending the outcome of investigation and inquiry currently being conducted by CBN.”

ALSO READ;

In another suit filed by CBN against Sethwealth Ventures and two others, the court granted an exparte application by the apex bank to freeze 50 accounts linked to the three defendants in 13 banks. A similar order was also made in the suit by CBN against Bluebeam Capital Ltd freezing 60 accounts of the company in 13 banks.

The 17 banks affected are Access Bank, First City Monument Bank, Fidelity Bank, Sterling Bank, Keystone Bank, Providus Bank, United Bank for Africa (UBA), Wema Bank and First Bank. Others are Guaranty Trust Bank, Ecobank Bank, Heritage Bank, Polaris Bank, Zenith Bank, Stanbic IBTC Bank, Standard Chartered Bank and Union Bank.

The companies affected include Bluebeam Capital Limited, Sethwealth Ventures, Seasons Bureau De Change, Lat-Ade Logistics, Sani Polo Global Investment Ltd, Saneo Global Resources Limited and Romvic Ventures Nigeria Limited.

 

Comments

Please follow and like us:

Continue Reading

Health

COVID-19 Vaccination: Oxford/AstraZeneca vaccine may Loose confidence to rare blood clots side-effect

Published

on

COVID-19 Vaccination

Oxford/AstraZeneca vaccine is the Option offered to under-30s after UK records 79 cases of rare blood clots out of 20m jabs administered

 

Experts warned of damage to confidence in the UK’s vaccine programme after 10 million adults under 30 were told they will be offered an alternative to the Oxford/AstraZeneca jab following concerns over rare blood clots.

Healthy 18 to 29-year-olds who are not at high risk of Covid should have the option of a different jab if one is available in their area, the government’s joint committee on vaccines and immunization (JCVI) said weeks after some European countries suspended the use of AstraZeneca jabs in younger people.

For older people, the benefits of the vaccine – the most widely-used in the UK – far outweigh the risks, the JCVI added. The UK has recorded 79 rare blood clots cases, 19 of whom died, out of 20m AstraZeneca jabs administered.

England’s deputy chief medical officer, Prof Jonathan Van-Tam, called the move “a course correction” and said there should be little or no impact on the vaccine rollout timeline, though he warned that under-30s could face short delays in getting inoculated.

Boris Johnson tweeted: “We will follow today’s updated advice, which should allow people of all ages to continue to have full confidence in vaccines, helping us save lives and cautiously return towards normality.”

Spain Cornella Astrazeneca Covid 19 Vaccine - 07 Apr 2021<br>Mandatory Credit: Photo by Xinhua/REX/Shutterstock (11848049c) A health worker prepares a dose of AstraZeneca COVID-19 vaccine at a vaccination site in Cornella, Spain, April 7, 2021. The European Medicines Agency (EMA) confirmed on Wednesday that the occurrence of blood clots with low blood platelets are strongly associated with the administration of AstraZeneca COVID-19 vaccine, but should be still listed as very rare side effects. Spain Cornella Astrazeneca Covid 19 Vaccine - 07 Apr 2021

The recommendation came as it was confirmed that the European regulator is examining whether other vaccines using similar technology to the AstraZeneca jab pose any risk.

There had been three cases of venous thromboembolism blood clots with low platelets involving the Johnson & Johnson jab, a European Medicines Agency (EMA) official said.

Symptoms of the rare brain blood clots include severe headaches and blurred vision, and most cases occur within two weeks of a jab – but such events are treatable if medical help is sought, experts said.

In the UK up to 31 March, there were 79 reports of these rare blood clots with low platelets – some but not all of them in the brain, it was revealed on Wednesday. Of those affected, 19 people died, although it is not known if the blood clots were the cause in every case.

More were women – 51 – and they were all aged 18-79. Three were under 30. But the recommendation of an alternative vaccine for that age group is because their risk from Covid itself is very low.

In older age groups, the experts believe, the benefits of vaccination significantly outweigh the rare side-effect risk, but in younger people “it is more finely balanced”.

Dr June Raine, CEO of the Medicines and Healthcare products Regulatory Authority (MHRA), said the risk was “extremely small” and the authority had not yet concluded that the vaccine was responsible.

“The evidence is firming up. While it is a strong possibility, more work is needed to establish beyond all doubt that the vaccine has caused this side-effect,” she said.

There are concerns, however, that confidence in the AstraZeneca jab has been hit.

“Today’s decision is a severe blow to the public’s vaccine confidence, which is already fragile,” said Dr Chris Papadopoulos, principal lecturer in public health at the University of Bedfordshire. It might be the right decision, but needed to be coupled to efforts to counter vaccine hesitancy, he added.

Prof Martin Hibberd, of the London School of Hygiene & Tropical Medicine, said it was a sensible decision. “However, I would like to see the evidence that the other vaccines are safer.”

The Royal College of Midwives said young people and pregnant women would be concerned.

“Although pregnant women who are clinically extremely vulnerable are eligible for the vaccine, those under 30 have seen their options severely limited, as the Pfizer/BioNTech vaccine is not approved for use for them,” said its executive director, Birte Harlev-Lam.

Pregnant women should discuss vaccination with their doctor. Those who have any history of blood clots should not have the AstraZeneca jab.

It came as the EMA said the rare blood clots would be listed formally as a side-effect of the AstraZeneca vaccine, though it did not announce any restrictions on use. Several EU countries, including France and Germany, have already limited use to citizens aged over 55 or 60, or suspended its use entirely.

Emer Cooke, executive director of the EMA, said: “In the UK, I cannot comment on the decision-making to restrict to a certain age but what I can tell you is there is a lot more use in the younger age groups in the UK than in the EU at the moment and we will certainly take this into account in our further evaluations.”

 

Asked why European countries have different stances from the UK, Adam Finn from the JCVI said Britain had “extremely detailed data” based on a high number of administered AstraZeneca jabs.

“I think other countries in Europe that have seen clusters of cases … they are not in such a good evidence-driven position to make their judgments,” he said, adding that “the risk-benefit [equation] does vary … from one country to another”.

The EMA said it could not identify the cause of the blood-clotting event, which was mostly, but not entirely, in women under 60.

It is advising that healthcare professionals and people getting the vaccine should be made aware of the issue and the symptoms of the clots, which range from shortness of breath and chest pain to persistent headaches and blurred vision.

“It is of great importance that healthcare professionals and people coming for vaccination are aware of these risks and look out for signs or symptoms,” said Cooke.

Like the EMA, the MHRA is a regulator and an adviser on safety and efficacy to governments.

The UK recommendation that under-30s should be offered an alternative vaccine comes from the JCVI. Its head, Prof Wei Shen Lim, said it had only made the recommendation to government “out of the utmost caution rather than because we have any serious safety concerns”.

Dr Peter Arlett, the head of the EMA data analytics and methods taskforce, said the agency was examining whether other vaccines posed any risk, citing cases of rare blood clots involving the Johnson & Johnson jab.

“There have been three cases with the Johnson & Johnson vaccine of blood clots associated with low platelets which have some similarities to these cases that we’ve been describing today,” he said.

“However, the numbers are extremely small compared with the 5 million patients that have received the Johnson & Johnson vaccine worldwide. This is, however, under close scrutiny, the [committee] is looking at it carefully, and I think it would be fair to say there’s intensive monitoring of this issue across the vaccines.”

A UK government spokesperson said: “The Oxford/AstraZeneca vaccine is safe, effective and has already saved thousands of lives.

“Everybody who has already had a first dose of the AstraZeneca vaccine should receive a second dose of the same brand, irrespective of age, except for the very small number of people who experienced blood clots with low platelet counts from their first vaccination.”

 

Comments

Please follow and like us:

Continue Reading

Let’s keep you updated

Advertisement

Instagram

Recent Tweets

Subscribe

Trust you had a great time reading our headlines. Kindly drop your email address to subscribe to our blog and receive notifications of new posts .

Join 6,808 other subscribers

Trending

error

We know you enjoy our storylines. Please spread the word to your friends :)

%d bloggers like this:
Enable Notifications    OK No thanks